Clinical Trial Update: A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for RLY-2608, a mutant-selective PI3Kα inhibitor, in adults and children with PIK3CA-related overgrowth spectrum and related vascu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cloves Syndrome
• Klippel-trénaunay Syndrome
• Lymphatic Malformation
• Megalencephaly-capillary-malformation-polymicrogyria Syndrome
• Pik3ca-related Overgrowth Spectrum
• Vascular Malformation

Drugs mentioned

• RLY-2608

Snippet

Sponsor: Relay Therapeutics, Inc. | Conditions: PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations | Phase 2 | Status: RECRUITING